List view / Grid view
28 May 2015 | By Victoria White
Top line results have been announced from the GS-4774 Phase 2 study in patients with HBV on long term viral suppression with an oral antiviral treatment...
13 April 2015 | By Victoria White
Ichor Medical Systems has announced that it has entered into a product development collaboration and worldwide license agreement with Janssen...
4 December 2014 | By Bristol-Myers Squibb Foundation
The Bristol-Myers Squibb Foundation announced nine new grants totaling more than $3.5 million to strengthen efforts in China and India in the fight against hepatitis B virus (HBV) and hepatitis C virus (HCV) infection by focusing on the most vulnerable, high-risk patient populations...
28 August 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that it has signed a cooperative sales agreement with The Chemo-Sero-Therapeutic Research Institute on August 22 for its recombinant adsorbed hepatitis B vaccine (yeast-derived), Bimmugen®...
Gilead Sciences, Inc. (NASDAQ:GILD) announced today at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool (MPP) to expand access to Gilead’s investigational drug tenofovir alafenamide (TAF) for HIV and hepatitis B, contingent on the medicine’s U.S. regulatory approval.
18 April 2012 | By Gilead Sciences
Presentations include first results for lead hepatitis C candidate GS-7977 in treatment-naïve genotype 1 patients...
18 February 2012 | By Bristol-Myers Squibb
Three new grants awarded...
Abbott announced it has received CE Marking (Conformité Européenne) in the European Union to market a new, highly sensitive diagnostic test for detection of hepatitis B surface antigen (HBsAg). The test is performed on Abbott’s ARCHITECT® system. Hepatitis B is an inflammatory liver disease caused by the hepatitis B virus…
5 November 2011 | By
New long-term data show no development of resistance...
